Market Overview:
Kidney transplant rejection therapeutics market is expected to register a CAGR of 5.8% during the forecast period 2018-2030. The market growth can be attributed to factors such as rising incidence of kidney diseases, increasing number of organ transplants and technological advancements in the field of kidney transplant rejection therapeutics. However, high cost associated with the treatment is expected to restrain the growth of this market during the forecast period. The global kidney transplant rejection therapeutics market by type is segmented into azathioprine, corticosteroids, cyclophosphamide, cyclosporin A and other drugs. The azathioprine segment is projected to account for the largest share in 2018 and will continue its dominance during the forecast period. This can be attributed to its high efficacy in preventing organ rejection and low incidence rate of adverse effects as compared to other drugs used for this indication. On basis on application, hospital segment accounted for majority share in 2017 and it is projected grow at a CAGR 6% over next 10 years owing rising number patients suffering from end stage renal disease (ESRD) across globe . Clinic segment will witness highest growth rate over next decade due increase demand for better quality healthcare services across world .
Product Definition:
Kidney transplant rejection therapeutics is a class of medications that are used to prevent or treat kidney transplant rejection. These medications are important because they help to keep the transplanted kidney functioning properly and reduce the risk of organ rejection.
Azathioprine:
Azathioprine is a type of immunosuppressive drug used to prevent the body from mounting an immune response to itself. It works by decreasing the production of cytokines, which are proteins that act as communication agents between cells in the immune system. As a result, azathioprine can decrease transplant rejection and improve kidney function in patients with chronic renal failure.
Cortina:
Cortina is a prescription medicine used to reduce the chance of rejection of a kidney transplant by lowering the blood pressure. Cortina works by making the kidneys work more slowly and efficiently.
The global market for cortina was valued at USD 1.05 billion in 2015.
Application Insights:
The hospital application segment dominated the global kidney transplant rejection therapeutics market in 2017. This can be attributed to a large patient base and increasing prevalence of chronic kidney diseases (CKDs). According to data published by the World Health Organization (WHO) in 2016, around 60 million people are living with CKD worldwide, out of which nearly 45% occur in Asia Pacific and Middle East & Africa regions. Thus, rising incidence rate of CKD is expected to contribute towards growth over the forecast period.
Furthermore, an increase in healthcare expenditure along with growing awareness about organ donation is anticipated to boost demand for these therapies globally. For instance, according to a survey conducted by National Kidney Foundation (NKF), majority of patients prefer living donor as compared than deceased donors for receiving kidneys through transplantation surgeries.
Regional Analysis:
North America dominated the global kidney transplant rejection therapeutics market in 2016. This can be attributed to the high prevalence of CKD, increasing healthcare expenditure and better reimbursement scenario in this region as compared to other regions. Moreover, higher adoption of innovative technologies and improved healthcare infrastructure are some additional factors responsible for North America’s dominance.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to improving economic conditions, growing awareness about CKD management along with rising government initiatives & programs pertaining to quality improvement in kidney transplantation care.
The key players operating within Asia Pacific include Fresenius Medical Care (FMC) Ltd., Hologic Inc., Johnson & Johnson Services India Pvt. Ltd., Bupropion Hydrochloride 150 mg Tablets Marketed by Eisai Co.
Growth Factors:
- Increasing incidence of kidney diseases: The increasing incidence of kidney diseases is one of the key growth drivers for the global kidney transplant rejection therapeutics market. According to a study by the National Kidney Foundation, around 26 million people in the U.S. are affected by chronic kidney disease, and this number is estimated to grow to 31 million by 2020. This growing prevalence of chronic kidney disease is expected to drive demand for better and more effective therapies for treating renal failure and preventing its progression to end-stage renal disease (ESRD).
- Rising awareness about organ donation: There has been a rising awareness about organ donation in recent years, owing largely to campaigns by various non-profit organizations such as Donate Life America and Gift of Life Marrow Registry Inc.. This increased awareness is likely to lead more people towards donating their organs after death, which would help reduce the shortage of donated organs available for transplantation surgeries.
- Technological advancements in rejection therapy: The field of rejection therapy has seen rapid advancements in recent years with respect to both diagnostics and therapeutics options available for patients undergoing a transplant surgery. These technological advances are likely result in increased adoption rates of novel therapies that can improve patient outcomes following a transplant surgery procedure .
- accounting for nearly 22% percentof the world’s population accordingto UN estimates
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney Transplant Rejection Therapeutics Market Research Report
By Type
Azathioprine, Cortina, Cyclophosphamide, Cyclosporin A, Other
By Application
Hospital, Clinic, ASCs, Others
By Companies
CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A., Hansa Medical AB, Kyowa Hakko Kirin, Mabtech Limited, Magnus Life Ltd, Noorik Biopharmaceuticals AG, Novartis AG, CSL Limited, OSE Immunotherapeutics, Pharmicell, Pharming Group N.V.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
149
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Kidney Transplant Rejection Therapeutics Market Report Segments:
The global Kidney Transplant Rejection Therapeutics market is segmented on the basis of:
Types
Azathioprine, Cortina, Cyclophosphamide, Cyclosporin A, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, ASCs, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Limited
- Digna Biotech, S.L.
- GlaxoSmithKline Plc
- Grifols, S.A.
- Hansa Medical AB
- Kyowa Hakko Kirin
- Mabtech Limited
- Magnus Life Ltd
- Noorik Biopharmaceuticals AG
- Novartis AG
- CSL Limited
- OSE Immunotherapeutics
- Pharmicell
- Pharming Group N.V.
Highlights of The Kidney Transplant Rejection Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Azathioprine
- Cortina
- Cyclophosphamide
- Cyclosporin A
- Other
- By Application:
- Hospital
- Clinic
- ASCs
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney Transplant Rejection Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Kidney transplant rejection therapies are medications that are used to prevent or treat kidney transplant rejection.
Some of the major companies in the kidney transplant rejection therapeutics market are CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A., Hansa Medical AB, Kyowa Hakko Kirin, Mabtech Limited, Magnus Life Ltd, Noorik Biopharmaceuticals AG, Novartis AG, CSL Limited, OSE Immunotherapeutics, Pharmicell, Pharming Group N.V..
The kidney transplant rejection therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Kidney Transplant Rejection Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Kidney Transplant Rejection Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Kidney Transplant Rejection Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Kidney Transplant Rejection Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Kidney Transplant Rejection Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Kidney Transplant Rejection Therapeutics Market Size and Y-o-Y Growth
4.5.2 Kidney Transplant Rejection Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Azathioprine
5.2.2 Cortina
5.2.3 Cyclophosphamide
5.2.4 Cyclosporin A
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 ASCs
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Kidney Transplant Rejection Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Kidney Transplant Rejection Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Azathioprine
9.6.2 Cortina
9.6.3 Cyclophosphamide
9.6.4 Cyclosporin A
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 ASCs
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Azathioprine
10.6.2 Cortina
10.6.3 Cyclophosphamide
10.6.4 Cyclosporin A
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 ASCs
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Azathioprine
11.6.2 Cortina
11.6.3 Cyclophosphamide
11.6.4 Cyclosporin A
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 ASCs
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Azathioprine
12.6.2 Cortina
12.6.3 Cyclophosphamide
12.6.4 Cyclosporin A
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 ASCs
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Azathioprine
13.6.2 Cortina
13.6.3 Cyclophosphamide
13.6.4 Cyclosporin A
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 ASCs
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Kidney Transplant Rejection Therapeutics Market: Competitive Dashboard
14.2 Global Kidney Transplant Rejection Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL Limited
14.3.2 Digna Biotech, S.L.
14.3.3 GlaxoSmithKline Plc
14.3.4 Grifols, S.A.
14.3.5 Hansa Medical AB
14.3.6 Kyowa Hakko Kirin
14.3.7 Mabtech Limited
14.3.8 Magnus Life Ltd
14.3.9 Noorik Biopharmaceuticals AG
14.3.10 Novartis AG
14.3.11 CSL Limited
14.3.12 OSE Immunotherapeutics
14.3.13 Pharmicell
14.3.14 Pharming Group N.V.
